StockpollyBeta
Get App
Popularity #954
SYRE · NASDAQ · Biotechnology

Spyre Therapeutics (SYRE)

Develops extended-half-life antibody combinations for bowel, rheumatic, and dermatologic diseases.

$87.56
vs last close−4.41 (−4.80%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0000000009000
Cost of revenue00000000454500
Gross profit00000000−454500
1846484455615442121024642
Research & development253435334550424045456066
91413121111121212131516
General & administrative91413121111121212131516
Other expenses−15−200000−10−4545−30−40
Operating income−18−46−48−44−55−61−54−42−57−57−46−42
−22−1745−1459546−5−235
Interest income1446566657710
Other non-operating income152−4−514−5−910−46530−5
Income before tax−40−63−44−39−69−56−45−37−11−63−69−36
Income tax expense000000000000
Net income from continuing operations−40−63−44−39−69−56−45−37−11−63−69−36
Net income−40−63−44−39−69−56−45−37−11−63−69−36
EPS, basic−$9.34−$2.91−$1.20−$0.86−$1.36−$0.15−$0.13−$0.60−$0.15−$0.70−$0.74−$0.36
EPS, diluted−$9.34−$2.91−$1.20−$0.86−$1.36−$0.15−$0.13−$0.60−$0.15−$0.70−$0.74−$0.36
Weighted average shares, basic42237455147606160757985
Weighted average shares, diluted42237455147606160757985
EBITDA−33−48−44−39−69−56−45−52−11−63−76−36
Depreciation & amortization000000000000
EBIT−33−48−44−39−69−56−45−52−11−63−76−36